

# **Biograil ApS**

Langebjerg 1, 4000 Roskilde CVR no. 40 66 66 99

# Annual report for 2023

Årsrapporten er godkendt på den ordinære generalforsamling, d. 11.06.24

Jens Ahrendt Dirigent

This document contains a Danish version as well as an English version. In the event of any disputes or misunderstandings regarding the interpretation of this document, the Danish version of the document shall prevail. STATSAUTORISERET REVISIONSPARTNERSELSKAB København Tel. 39 16 7



København Knud Højgaards Vej 9 2860 Søborg

Tel. 39 16 76 00 www.beierholm.dk CVR-nr. 32 89 54 68

Company information etc.	3
Statement by the Executive Board and Board of Directors on the annual report	4
Independent auditor's report	5 - 7
Management's review	8
Income statement	9
Balance sheet	10 - 11
Statement of changes in equity	12
Notes	13 - 22



# The company

Biograil ApS Langebjerg 1 4000 Roskilde Danmark Website: https://biograil.com/ Registered office: Roskilde CVR no.: 40 66 66 99 Financial year: 01.01 - 31.12

# **Executive Board**

Karsten Lindhardt

#### **Board of Directors**

Anke Cassing John Michael Barberich Lars Hellerung Christiansen

#### Auditors

Beierholm Statsautoriseret Revisionspartnerselskab



# Statement by the Executive Board and Board of Directors on the annual report

We have on this day presented the annual report for the financial year 01.01.23 - 31.12.23 for Biograil ApS.

The annual report is presented in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the company's assets, liabilities and financial position as at 31.12.23 and of the results of the company's activities for the financial year 01.01.23 - 31.12.23.

We believe that the management's review includes a fair review of the matters dealt with in the management's review.

The annual report is submitted for adoption by the general meeting.

Roskilde, June 11, 2024

# **Executive Board**

Karsten Lindhardt

# **Board of Directors**

Anke Cassing

John Michael Barberich

Lars Hellerung Christiansen



# To the capital owner of Biograil ApS

#### **Qualified Opinion**

We have audited the financial statements of Biograil ApS for the financial year 01.01.23 - 31.12.23, which comprise income statement, balance sheet, statement of changes in equity and notes to the financial statements, including significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, except for the possible effects of the matter described in the Basis for qualified opinion paragraph, the financial statements give a true and fair view of the company's financial position at 31.12.23 and of the results of the company's operations for the financial year 01.01.23 - 31.12.23 in accordance with the Danish Financial Statements Act.

# **Basis for Qualified Opinion**

The item other long-term liabilities includes derivative financial instruments with an amount of DKK 10.165k. The liabilities are measured at fair value according to the management's estimate. We have not been able to obtain the necessary documentation for the determined fair value and are therefore not able to assess the management's estimate and the value of the liabilities.

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We are independent of the company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Statement on the management's review

Management is responsible for the management's review.

Our opinion on the financial statements does not cover the management's review, and we do not express any form of assurance conclusion thereon.



In connection with our audit of the financial statements, it is our responsibility is to read management's review and, in doing so, consider whether management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether management's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the management's review.

#### Management's responsibilities for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless management either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

#### Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Soeborg, Copenhagen, June 11, 2024

# Beierholm

Statsautoriseret Revisionspartnerselskab CVR no. 32 89 54 68

Thomas Thomsen State Authorized Public Accountant MNE-no. mne34079



# **Primary activities**

The company's activities comprise to develop advanced medical products.

# Development in activities and financial affairs

The income statement for the period 01.01.23 - 31.12.23 shows a profit/loss of DKK -34,799,433 against DKK 12,877,987 for the period 01.01.22 - 31.12.22. The balance sheet shows equity of DKK 10,017,542.

The management considers the net profit for the year to be as expected.

#### Subsequent events

No important events have occurred after the end of the financial year.



	2023	2022
	DKK	DKk
Gross result	-16,707,823	26,317,576
Staff costs	-16,553,861	-9,683,652
Profit/loss before depreciation, amortisation, write- downs and impairment losses	-33,261,684	16,633,924
Depreciation, amortisation and impairments losses of intan- gible assets and property, plant and equipment	-247,646	-156,999
Operating profit/loss	-33,509,330	16,476,925
Financial income Financial expenses	1,609,799 -9,806,503	3,453,520 -7,052,458
Profit/loss before tax	-41,706,034	12,877,987
Tax on profit or loss for the year	6,906,601	C
Profit/loss for the year	-34,799,433	12,877,987
Proposed appropriation account		
Retained earnings	-34,799,433	12,877,987
Total	-34,799,433	12,877,987



# ASSETS

Total assets	76,181,881	95,347,33 <sup>,</sup>
Total current assets	74,618,016	93,765,54
Cash	59,688,085	88,184,83
Total receivables	14,929,931	5,580,71
Prepayments	444,440	339,82
Other receivables	2,107,779	2,983,87
Income tax receivable	8,323,401	2,200,00
Trade receivables Receivables from group enterprises	3,921,693 132,618	57,01
	1,563,865	1,301,70
Total non-current assets		1,581,78
Total investments	346,285	314,61
Deposits	338,828	307,16
Equity investments in group enterprises	7,457	7,45
Total property, plant and equipment	729,110	697,28
Other fixtures and fittings, tools and equipment	729,110	697,28
Total intangible assets	488,470	569,88
Acquired rights	488,470	569,88
	31.12.23 DKK	31.12.2 DK



# EQUITY AND LIABILITIES

Total equity and liabilities	76,181,881	95,347,334
Total payables	66,164,339	50,530,359
Total short-term payables	4,777,439	2,210,005
Deferred income	83,300	333,200
Other payables	1,432,943	688,227
Trade payables	3,095,260	1,125,207
Payables to other credit institutions	165,936	63,371
Total long-term payables	61,386,900	48,320,354
Other payables	10,164,737	8,616,375
Convertible and profit-sharing debt instruments	51,222,163	39,703,979
Total equity	10,017,542	44,816,975
Retained earnings	9,770,066	44,569,499
Share capital	247,476	247,476
	DKK	DKK
	31.12.23	31.12.22

<sup>3</sup> Fair value information

4 Derivative financial instruments



Figures in DKK	Share capital	Retained earnings	Total equity
Statement of changes in equity for 01.01.23 - 31.12.23			
Balance as at 01.01.23 Net profit/loss for the year	247,476 0	44,569,499 -34,799,433	44,816,975 -34,799,433
Balance as at 31.12.23	247,476	9,770,066	10,017,542



	2023 DKK	2022 DKK
1. Staff costs		
Wages and salaries Pensions	13,970,804 2,095,312	8,683,438 654,741
Other social security costs	90,437	35,915
Other staff costs	397,308	309,558
Total	16,553,861	9,683,652
Average number of employees during the year	14	4

# 2. Long-term payables

Figures in DKK	Total payables at 31.12.23
Convertible and profit-sharing debt instruments Other payables	51,222,163 10,164,737
Total	61,386,900

The company has raised loans of EUR 2,179k and USD 5,000 in return for the issue of convertible debt instruments which entitle the lender to convert the loan (including accrued interests) into B-shares in the company at a price of EUR 200 per share at the maturity date. The right of conversion expires when the loan is repaid. The loan falls due for payment at mid-2024.

Pursuant to the terms and conditions of the notes, the loans can be repaid or converted prior to the maturity date at a variable price per share in case of certain events. Due to the terms and conditions of the notes, the loans are classified as "Convertible and profit-sharing debt instruments". "Other payables" consist of derivative financial instruments concerning the loans mentioned above.



### 3. Fair value information

	Derivative financial	T-t-l
Figures in DKK	instruments	Total
Fair value as at 31.12.23	10,164,737	10,164,737

Derivative financial instruments are related to convertible debt instruments as stated in note 2 "Long-term payables". At initial recognition, the loans are allocated to its liability components and derivative features respectively.

The value of the derivative feautures is determined by discounting the convertible debt instruments to present value using a discount factor of 20 percent.

It is the management's opinion that the fair value of the derivative financial instruments as at 31.12.2023 is similar to the value at initial recognition.

# 4. Derivative financial instruments

Derivative financial instruments are related to convertible debt instruments as stated in note 2 "Long-term payables". The loans carries interest at 8 percent.

The fair vaulue of the derivative financial instruments amounts to DKK 10,165k as at 31.12.2023 and is classified as "Other payables" in the balance sheet.



# 5. Accounting policies

#### GENERAL

The annual report is presented in accordance with the provisions of the Danish Financial Statements Act (*Årsregnskabsloven*) for enterprises in reporting class B with application of provisions for a higher reporting class.

The accounting policies have been applied consistently with previous years.

In accordance with section 110 of the Danish Financial Statements Act, the company has not prepared consolidated financial statements.

#### Basis of recognition and measurement

Income is recognised in the income statement as earned, including value adjustments of financial assets and liabilities. All expenses, including depreciation, amortisation, impairment losses and write-downs, are also recognised in the income statement.

Assets are recognised in the balance sheet when it is probable that future economic benefits will flow to the company, and the value of such assets can be measured reliably. Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow from the company, and the value of such liabilities can be measured reliably. On initial recognition, assets and liabilities are measured at cost. Subsequently, assets and liabilities are measured as described for each item below.

On recognition and measurement, account is taken of foreseeable losses and risks arising before the date at which the annual report is presented and proving or disproving matters arising on or before the balance sheet date.

# CURRENCY

The annual report is presented in Danish kroner (DKK).

On initial recognition, transactions denominated in foreign currencies are translated using the exchange rates applicable at the transaction date. Exchange rate differences between the exchange rate applicable at the transaction date and the exchange rate at the date of payment are recognised in the income statement as a financial item. Receivables, payables and other monetary items denominated in foreign currencies are translated using the exchange rates applicable at the balance sheet date. The difference between the exchange rate applicable at the balance sheet date and at the date at which the receivable or payable arose or was recognised in the latest annual report is recognised under financial income or expenses in the income statement. Fixed assets and other non-monetary assets acquired in foreign currencies are translated using historical exchange rates.



# DERIVATIVE FINANCIAL INSTRUMENTS

On initial recognition, derivative financial instruments are measured at cost. Subsequently, they are measured at fair value and recognised under other receivables and other payables, respectively.

Fair value adjustment of derivative financial instruments classified as and meeting the criteria for hedging future cash flows (cash flow hedging) are recognised in equity under the cash flow hedging reserve. In the event that the hedged transaction results in the recognition of an asset or a liability, the accumulated fair value adjustment of the hedging instrument, which was previously recognised in equity, will be included in the cost of the asset or the liability. In the event that the hedged transaction results in the recognition of an income or an expense, the accumulated fair value adjustment of the hedging instrument, which was previously recognised in equity, will be recognised together with the hedged income or expense.

If the hedged transaction is no longer expected to occur, the cash flow hedging treatment is discontinued, and the accumulated fair value adjustment of the hedging instrument is transferred to other net financials in the income statement. If the hedged transaction is still expected to occur, but the criteria for cash flow hedging are no longer met, the hedging treatment is discontinued, and the accumulated fair value adjustment of the hedging instrument remains in equity until the transaction occurs.

Fair value adjustments of derivative financial instruments that do not meet the criteria for hedge accounting treatment are recognised under other net financials in the income statement on an ongoing basis.

#### GRANTS

Grants are recognised when there is reasonable certainty that the grant conditions have been met and that the grant will be received.

Grants to cover expenses incurred are recognised on a proportionate basis in the income statement over the period in which the expenses eligible for grants are expensed. Grants are recognised under other operating income.

Grants received for the production or construction of assets are recognised as deferred income under payables. For depreciable and amortisable assets, the grant is recognised as the asset is depreciated or amortised.



#### **INCOME STATEMENT**

#### **Gross result**

Gross result comprises revenue, other operating income and raw materials and consumables and other external expenses.

#### Revenue

Income from the sale of services is recognised in the income statement in line with completion of services, which means that revenue corresponds to the selling price of the work performed for the year stated on the basis of the stage of completion at the balance sheet date (percentage of completion method).

#### Other operating income

Other operating income comprises income of a secondary nature in relation to the enterprise's activities, including rental income, negative goodwill and gains on the sale of intangible assets and property, plant and equipment.

#### Costs of raw materials and consumables

Costs of raw materials and consumables comprise raw materials and consumables used for the year as well as any changes in inventories, including any inventory wastage.

Write-downs of inventories of raw materials and consumables are also recognised under raw materials and consumables to the extent that these do not exceed normal write-downs.

#### Other external expenses

Other external expenses comprise costs relating to distribution, sales and advertising and administration, premises and bad debts to the extent that these do not exceed normal write-downs.

# Staff costs

Staff costs comprise wages and salaries as well as other staff-related costs.



# Depreciation, amortisation and impairment losses

The depreciation and amortisation of intangible assets and property, plant and equipment aim at systematic depreciation and amortisation over the expected useful lives of the assets. Assets are depreciated and amortised according to the straight-line method based on the following expected useful lives and residual values:

	Useful lives, years	Residual value DKK
Acquired rights	10	0
Other plant, fixtures and fittings, tools and equipment	5	0

The basis of depreciation and amortisation is the cost of the asset less the expected residual value at the end of the useful life. Moreover, the basis of depreciation and amortisation is reduced by any impairment losses. The useful life and residual value are determined when the asset is ready for use and reassessed annually.

Intangible assets and property, plant and equipment are impaired in accordance with the accounting policies referred to in the 'Impairment losses on fixed assets' section.

# Other net financials

Interest income and interest expenses, foreign exchange gains and losses on transactions denominated in foreign currencies etc. are recognised in other net financials.

#### Tax on profit/loss for the year

The current and deferred tax for the year is recognised in the income statement as tax on the profit/loss for the year with the portion attributable to the profit/loss for the year, and directly in equity with the portion attributable to amounts recognised directly in equity.

#### BALANCE SHEET

#### Intangible assets

#### Acquired rights

Aquired rights are measured in the balance sheet at cost less accumulated amortisation and impairment losses.

Acquired rights are amortised using the straight-line method based on useful lives, which are stated in the 'Depreciation, amortisation and impairment losses' section.

Gains or losses on the disposal of intangible assets are determined as the difference between the selling price, if any, less selling costs and the carrying amount at the date of disposal.

# Property, plant and equipment

Property, plant and equipment comprise other fixtures and fittings, tools and equipment.

Property, plant and equipment are measured in the balance sheet at cost less accumulated depreciation and impairment losses.

Cost comprises the purchase price and expenses resulting directly from the purchase until the asset is ready for use. Interest on loans arranged to finance production is not included in the cost.

Property, plant and equipment are depreciated using the straight-line method based on useful lives and residual values, which are stated in the 'Depreciation, amortisation and impairment losses' section.

Gains and losses on the disposal of property, plant and equipment are determined as the difference between the selling price, if any, less selling costs and the carrying amount at the date of disposal less any costs of disposal.

# Equity investments in group entreprises

Equity investments in subsidiaries are measured in the balance sheet at cost less any impairment losses. Transaction costs directly attributable to the acquisition are recognised in the cost of equity investments.

Gains or losses on disposal of equity investments are determined as the difference between the disposal consideration and the carrying amount of net assets at the time of sale, including non-amortised goodwill, as well as the expected costs of divestment or discontinuation. Gains and losses are recognised in the income statement under income from equity investments.



# Impairment losses on fixed assets

The carrying amount of fixed assets which are not measured at fair value is assessed annually for indications of impairment over and above what is reflected in depreciation and amortisation.

If the company's realised return on an asset or a group of assets is lower than expected, this is considered an indication of impairment.

If there are indications of impairment, an impairment test is conducted of individual assets or groups of assets.

If dividends are distributed on equity investments in subsidiaries exceeding the year earnings from the enterprise in question, this is considered an indication of impairment.

The assets or groups of assets are impaired to the lower of recoverable amount and carrying amount.

The higher of net selling price and value in use is used as the recoverable amount. The value in use is determined as the present value of expected net cash flows from the use of the asset or group of assets as well as expected net cash flows from the sale of the asset or group of assets after the expiry of their useful lives.

Impairment losses are reversed when the reasons for the impairment no longer exist.

#### Receivables

Receivables are measured at amortised cost, which usually corresponds to the nominal value, less write-downs for bad debts.

Write-downs for bad debts are determined based on an individual assessment of each receivable if there is no objective evidence of individual impairment of a receivable. Deposits recognised under assets comprise deposits paid to the lessor under leases entered into by the company.

#### Prepayments

Prepayments recognised under assets comprise costs incurred in respect of subsequent financial years.



# Cash

Cash includes deposits in bank account.

# Current and deferred tax

Current tax payable and receivable is recognised in the balance sheet as tax computed on the basis of the taxable income for the year, adjusted for tax paid on account.

Deferred tax liabilities and tax assets are recognised on the basis of all temporary differences between the carrying amounts and tax bases of assets and liabilities. However, deferred tax is not recognised on temporary differences relating to goodwill which is non-amortisable for tax purposes and other items where temporary differences, except for acquisitions, have arisen at the date of acquisition without affecting the net profit or loss for the year or the taxable income. In cases where the tax value can be determined according to different taxation rules, deferred tax is measured on the basis of management's intended use of the asset or settlement of the liability.

Deferred tax assets are recognised, following an assessment, at the expected realisable value through offsetting against deferred tax liabilities or elimination in tax on future earnings.

Deferred tax is measured on the basis of the tax rules and at the tax rates which, according to the legislation in force at the balance sheet date, will be applicable when the deferred tax is expected to crystallise as current tax.

# Payables

Convertible debt instruments are issued on terms that entitle the lender to convert the loan into equity interests in the company.

Long-term payables are measured at cost at the time of contracting such liabilities (raising of the loan). The payables are subsequently measured at amortised cost where capital losses and loan expenses are recognised in the income statement as a financial expense over the term of the payable on the basis of the calculated effective interest rate in force at the time of contracting the liability.

Short-term financial payables are measured at amortised cost, normally corresponding to the nominal value of such payables. Other short-term payables are measured at net realisable value.

# **Deferred** income

Deferred income under liabilities comprises payments received in respect of income in subsequent financial years.

